Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on Sofosbuvir-Daclatasvir, Lithium, or Trifluoperazine versus standard of care for hospitalized adults with COVID-19
IRCT20130812014333N147Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Apr 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of sofosbuvir, daclatasvir, lithium, trifluoperazine, hydroxychloroquine and 1 more in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoint: Hospitalization. Started Apr 2020; status: completed.
02
Drugs
sofosbuvirdaclatasvirlithiumtrifluoperazinehydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20130812014333N147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130812014333N147.